Octreotide capsules (Mycapssa®) have established clinical efficacy in maintaining normalization of GH and IGF-1 levels equivalent to those of parenteral octreotide injections in trials of both healthy patients and those with diagnosed acromegaly. The gene discussed is IGF1; the disease is acromegaly.